menu

TEAM

Scott M. Rocklage, PhD

Managing Partner

Scott M. Rocklage, Ph.D. joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. Dr. Rocklage has over three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan™, Teslascan® and Cubicin®). Dr. Rocklage has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar and has also held R&D positions at Salutar and Catalytica. Dr. Rocklage formerly served as Board Chairman of Relypsa (NASDAQ: RLYP) and Novira (acquired by J&J). He currently serves as Board Chairman of Rennovia, Kinestral and Cidara (NASDAQ: CDTX) as well as on the Boards of Epirus (NASDAQ: EPRS) and Pulmatrix (NASDAQ: PULM). Dr. Rocklage was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed) and Semprus (acquired by Teleflex). Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. in Chemistry from MIT where he conducted research in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005).   He is an inventor or co-inventor of over 30 U.S. patents and has more than 100 peer-reviewed publications.  Dr. Rocklage is based in the Boston, MA office.